[Summary] The company is primarily engaged in the research and development and p
Established in August 2000, Biotech Pharmaceutical Co., Ltd. is the highest-level and largest-investment cooperative project between China and Cuba in the field of biotechnology. The company focuses on the research, development, and production of humanized monoclonal antibodies and vaccines for the treatment of malignant tumors, and has undertaken major projects such as the National High-Tech Research and Development Program (863 Program) and the National High-Tech Industrialization Demonstration Project. Biotech Pharmaceutical possesses China's first world-class humanized antibody technology platform, representing the core technology and mainstream direction of international biopharmaceutical development. The company has designed and built China's first fully automated large-scale mammalian cell culture production line, which is currently the largest, best-equipped, and most technologically advanced large-scale cell culture technology platform in China. Biotech Pharmaceutical successfully developed China's first humanized monoclonal antibody drug -泰欣生TM Nimotuzumab, which obtained the Category I Biological New Drug Certificate issued by the State Food and Drug Administration in April 2005, filling the gap in China's humanized monoclonal antibody drugs. 泰欣生TM can specifically target tumor cells for targeted therapy, killing tumor cells without damaging normal tissues, representing the latest development direction in the field of tumor treatment. Clinical studies have shown that 泰欣生TM, alone or in combination with radiotherapy and chemotherapy, is highly effective against various cancers such as head and neck cancer, colorectal cancer, glioma, and non-small cell lung cancer, with low side effects and high clinical application value. While actively carrying out international technology transfer, Biotech Pharmaceutical is committed to cultivating independent innovation capabilities. New drugs under development include EGF vaccine for cancer treatment, humanized anti-CD6 monoclonal antibody for psoriasis and rheumatoid arthritis, and anti-CD3 monoclonal antibody for reversing organ transplant rejection. The developing Biotech Pharmaceutical aims to become a modern large-scale biopharmaceutical enterprise, with the purpose of improving the R&D capability and production level of antibody drugs and enhancing people's health. Through an internationalized, industrialized, standardized, and scaled operation model, it is committed to integrating the latest achievements of biotechnology development into the health industry in the 21st century, continuously contributing the most advanced and excellent antibody drugs to society, and witnessing the rise of China's life sciences and biomedicine with you!
What does Biotech Pharmaceutical Co., Ltd. require? Who is Biotech Pharmaceutical hiring? Biotech Pharmaceutical recruitment: 销售类占比最多占61.6%，其次是医疗卫生/美容保健类占53.4%. What education can get in at Biotech Pharmaceutical? 大专占比最多占60.5%，其次是本科占28.7%. High education required at Biotech Pharmaceutical? 硕士占7.7%，博士占1.2%. Work experience required at Biotech Pharmaceutical? 1-3年占比最多占47.1%，其次是不限占28.7%. Where are the job locations at Biotech Pharmaceutical? 北京占比最多占30.1%，其次是长治占13.2%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
